Pfizer Nears $7.3 Billion Acquisition of Anti-Obesity Drugmaker Metsera

Gelonghui September 22 | According to the Financial Times, Pfizer is nearing a $7.3 billion acquisition of weight-loss drug company Metsera. Pfizer will pay $47.50 per share in cash to Metsera, with an additional $22.50 per share contingent on reaching certain performance milestones, valuing the company at up to $7.3 billion.